Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2018

01-04-2018 | Letter to the Editor

Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

Author: Ahmet Emre Eskazan

Published in: International Journal of Clinical Oncology | Issue 2/2018

Login to get access

Excerpt

With the advent of imatinib—the first tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML)—managing patients with CML in the chronic phase (CML-CP) has changed dramatically. Second-generation TKIs (2GTKIs) are more potent than imatinib and can be a better option. Nilotinib and dasatinib were superior to imatinib regarding speed and depth of responses, with no significant benefit in long-term outcomes, including progression-free and overall survivals (PFS and OS) over imatinib in the frontline setting [1]. …
Literature
1.
Eskazan AE, Ozmen D (2017) Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events—is better always good? Expert Rev Hematol 10(7):583–586CrossRefPubMed
2.
Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128(1):17–23CrossRefPubMed
3.
Shiseki M, Yoshida C, Takezako N et al (2017) Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Int J Clin Oncol. 22:972–979CrossRefPubMedPubMedCentral
4.
Soverini S, Hochhaus A, Nicolini FE et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215CrossRefPubMed
5.
Eskazan AE, Eyice D, Kurt EA et al (2014) Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res 38(7):781–787CrossRefPubMed
6.
Ozgur Yurttas N, Sadri S, Keskin D et al (2015) Real-life data and a single center experience on dasatinib-induced pulmonary arterial hypertension in patients with Philadelphia chromosome-positive leukemias. Blood 126(23):4037 (Abstract)
7.
Kirkizlar O, Eskazan AE (2016) Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Rev Qual Life Cancer Care 1(5):353–359CrossRef
Metadata
Title
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib
Author
Ahmet Emre Eskazan
Publication date
01-04-2018
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1214-y

Other articles of this Issue 2/2018

International Journal of Clinical Oncology 2/2018 Go to the issue

Original Article

Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial

Original Article

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy

Special Article

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer

Original Article

Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer

Original Article

Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment

Review Article

Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits